Farmakogenetik Yönden Bireyler Arası Farmakokinetik Varyasyonlar
Yükleniyor...
Tarih
2017
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Farmakogenetik (PGx), genetik varyasyonlar ve bunların bireyler arasında oluşturduğu ilaç yanıtı farklılıkları ile ilgilenir. İlaç metabolizmasından sorumlu enzimlerin keşfi ve bu enzimleri kodlayan DNA dizilimlerinin araştırılması bireysel tedavi stratejilerinin oluşturulmasını sağlar. İlaç metabolizmasından sorumlu sitokrom 2B6, sitokrom 2C9, sitokrom 2C19, sitokrom 2D6, sitokrom 3A4, N-asetil transferaz, dihidropirimidin dehidrogenaz, tiopurin metiltransferaz, 5’-difosfat (UDP)-glukuronoziltransferaz ve katekol-O-metil transferaz enzim polimorfizleri ilacın farmokokinetik özelliğini etkileyerek bireyler arası ilaç yanıtı farklılıklarına neden olabilirler. PGx çalışmaların temelini oluşturan ilk örnekler N- asetil transferaz ve sitokrom 2D6 polimorfizmleridir. İlaç seçiminde ciddi farmakokinetik farklılıklara neden olan enzim polimorfizmlerinin göz önünde bulundurulması tedavi başarısını artırmak ve advers/toksik reaksiyon riskini önlemek açısından önemlidir. Yaklaşık 50 yıl önce temelleri atılan farmakogenetik ile ilgili çalışmalar gen teknolojisinin gelişmesi ile günümüzde daha önemli bir hale gelmiştir. Teknolojik gelişmeler sayesinde hızlanan farmakogenetik çalışmalar ile bireye özgü ilaç seçimi farmakogenetiğin ikinci 50 yılı içerisinde daha fazla gelişme kaydederek önemli bir parametre olacaktır.
Pharmacogenetics deals with genetic variations and individual response differences of drugs . The discovery of enzymes responsible for drug metabolism and the research to DNA sequences encoding these enzymes enable the creation of individual treatment strategies. Cytochrome 2B6, cytochrome 2C9, cytochrome C19, cytochrome 2D6, cytochrome 3A4, N-acetyltransferase, dihydropyrimidine dehydrogenase, thiopurine methyltransferase, UDP-glucuronyl transferase and catechol-O-methyltransferase enzymes are mainlyresponsible from drug metabolism and polymorphisms in enzyme activities affect the pharmacokinetic properties of the drug which leads to differences in drug response between individuals. First examples that form of the basis of pharmacogenetic studies are N-acetyltransferase and cytochrome 2D6 polymorphisms. Consideration of enzyme polymorphisms that may result with pharmacokinetic differences during drug choice is important to increase the success of treatment and to prevent adverse/toxic reaction risk. The studies about pharmacogenetics, which was studied about 50 years ago, has become more important nowadays with the development of gene technology. Individual drug choice will be an important parameter by further development of pharmacogenetics in the second 50 years through pharmacogenetic studies that is accelerated due to technological developments.
Pharmacogenetics deals with genetic variations and individual response differences of drugs . The discovery of enzymes responsible for drug metabolism and the research to DNA sequences encoding these enzymes enable the creation of individual treatment strategies. Cytochrome 2B6, cytochrome 2C9, cytochrome C19, cytochrome 2D6, cytochrome 3A4, N-acetyltransferase, dihydropyrimidine dehydrogenase, thiopurine methyltransferase, UDP-glucuronyl transferase and catechol-O-methyltransferase enzymes are mainlyresponsible from drug metabolism and polymorphisms in enzyme activities affect the pharmacokinetic properties of the drug which leads to differences in drug response between individuals. First examples that form of the basis of pharmacogenetic studies are N-acetyltransferase and cytochrome 2D6 polymorphisms. Consideration of enzyme polymorphisms that may result with pharmacokinetic differences during drug choice is important to increase the success of treatment and to prevent adverse/toxic reaction risk. The studies about pharmacogenetics, which was studied about 50 years ago, has become more important nowadays with the development of gene technology. Individual drug choice will be an important parameter by further development of pharmacogenetics in the second 50 years through pharmacogenetic studies that is accelerated due to technological developments.
Açıklama
Anahtar Kelimeler
Farmakogenetik, Polimorfizm, Sitokrom, Faz enzimleri, Bireysel ilaç yanıtı, Pharmacogenetic, Polymorphism, Cytochrome, Phase enzymes, İndividual drug response
Kaynak
Selçuk Tıp Dergisi
WoS Q Değeri
Scopus Q Değeri
Cilt
33
Sayı
4
Künye
Şahin, A. S., Soner, B. C., Kılıç, M., Al, M. (2017). Farmakogenetik yönden bireyler arası farmakokinetik varyasyonlar. Selçuk Tıp Dergisi, 33, 4, 82-90.
